Portal de Periódicos da CAPES

Exacerbation of myasthenia by propafenone.

1991; BMJ; Volume: 54; Issue: 4 Linguagem: Inglês

10.1136/jnnp.54.4.377

1468-330X

Bryan Lecky, Duncan L. Weir, Euming Chong,

Parkinson's Disease and Spinal Disorders

Letters to the Editor of buspirone (15 and 30 mg) did not lead to increased Parkinsonian disability and a beneficial effect was maintained over two weeks of treatment.Subsequent cessation of buspirone for 48 hours led to immediate deterioration of dyskinesias.Both patients requested reintroduction of buspirone and have now been treated with constant benefit for two months.The drug was generally well tolerated: three patients reported occasional light- headedness during the first days of dose increment and in one patient pre-existing benign visual hallucinations present with levodopa and apomorphine became more intense with 15 mg of buspirone.All patients experienced a heightened degree of relaxation and tranquillity.These preliminary results provide some evidence that in a dose of 15-30 mg a day buspirone may be useful in producing selec- tive anti-dyskinetic effects.Whether this occurs through its D2 antagonist actions or a non-specific anxiolytic action is unclear.We thank Bristol-Meyers Pharma- ceuticals, UK, for supplies of drugs.